Table 1 Workflow summary of single-cell transcriptomic studies that analyzed patient-derived CTCs
Cancer type | CTC enrichment | CTC criteria (micromanipulation) | Single-cell profiling | Number of CTCs (number of patients)a | Reference |
|---|---|---|---|---|---|
Multiple myeloma | FACS with serial dilution | CD45−, CD138+ | SMART-seq2 | 21 (2) | |
Colon | CellSearch® | CD45-, EpCAM+ | Multiplex PCR | 11 (8) | |
Ovary | Biocoll separation, Dynabeads® CD45 depletion | DAPI+, CK/EpCAM+, CD45- | Multiplex PCR | 15 (3) | |
Breast | MagSweeper® | EpCAM+ | Microfluidic RT-PCRb | 105 (50) | |
|  | Microfluidic negCTC-iChip | EpCAM/HER2/CDH11+, CD45/CD16/CD14− | Optimized Tang’s method | 15 (10) | |
|  | Microfluidic CTC-iChip | EpCAM/HER2/EGFR+, CD45− | SMART-seq v4c | 15 (10) | |
|  | Microfluidic ClearCell® FX | CD45/CD31−, Calcein+ d | PolarisTM IFC | 68 (4) | |
Melanoma | MagSweeper® | CD45−, Calcein+ | SMART-seq | 6 (1) | |
Prostate | MagSweeper® | CD45-, EpCAM+, DAPI- | SMART-seq, Advantage 2 PCR (Clontech) | 20 (4) | |
|  | ScreenCell® | CD45− | Microfluidic RT-PCRe | 38 (9) | |
|  | Microfluidic CTC-iChip | CD45-, EpCAM/CDH11+ | Modified Tang’s method | 77 (13) | |
Lung | Integrated nanoplatform | EpCAM+ | Multiplex PCR | 8 (1), 18 (1), 74 (1) | |
|  | Microfluidic ClearCell® FX | CD45− f | Multiplex PCR | 61 (20) | |
Prostate, breast | CellSearch®, ParsortixTM | EpCAM/pan-keratins+ | Multiplex PCR | 13 (1), 8 (1) | |
Pancreas, breast, prostate | Microfluidic CTC-iChip | CD45− | Modified Tang’s method | 7 (−), 29 (−), 77 (−) |
